376 related articles for article (PubMed ID: 26961355)
1. Time-evolution of in vivo protein corona onto blood-circulating PEGylated liposomal doxorubicin (DOXIL) nanoparticles.
Hadjidemetriou M; Al-Ahmady Z; Kostarelos K
Nanoscale; 2016 Apr; 8(13):6948-57. PubMed ID: 26961355
[TBL] [Abstract][Full Text] [Related]
2. In Vivo Biomolecule Corona around Blood-Circulating, Clinically Used and Antibody-Targeted Lipid Bilayer Nanoscale Vesicles.
Hadjidemetriou M; Al-Ahmady Z; Mazza M; Collins RF; Dawson K; Kostarelos K
ACS Nano; 2015 Aug; 9(8):8142-56. PubMed ID: 26135229
[TBL] [Abstract][Full Text] [Related]
3. The Human In Vivo Biomolecule Corona onto PEGylated Liposomes: A Proof-of-Concept Clinical Study.
Hadjidemetriou M; McAdam S; Garner G; Thackeray C; Knight D; Smith D; Al-Ahmady Z; Mazza M; Rogan J; Clamp A; Kostarelos K
Adv Mater; 2019 Jan; 31(4):e1803335. PubMed ID: 30488990
[TBL] [Abstract][Full Text] [Related]
4. In vivo formation of protein corona on gold nanoparticles. The effect of their size and shape.
García-Álvarez R; Hadjidemetriou M; Sánchez-Iglesias A; Liz-Marzán LM; Kostarelos K
Nanoscale; 2018 Jan; 10(3):1256-1264. PubMed ID: 29292433
[TBL] [Abstract][Full Text] [Related]
5. In Situ Characterization of Protein Adsorption onto Nanoparticles by Fluorescence Correlation Spectroscopy.
Shang L; Nienhaus GU
Acc Chem Res; 2017 Feb; 50(2):387-395. PubMed ID: 28145686
[TBL] [Abstract][Full Text] [Related]
6. The protein corona of circulating PEGylated liposomes.
Palchetti S; Colapicchioni V; Digiacomo L; Caracciolo G; Pozzi D; Capriotti AL; La Barbera G; Laganà A
Biochim Biophys Acta; 2016 Feb; 1858(2):189-96. PubMed ID: 26607013
[TBL] [Abstract][Full Text] [Related]
7. Influence of dynamic flow environment on nanoparticle-protein corona: From protein patterns to uptake in cancer cells.
Palchetti S; Pozzi D; Capriotti AL; Barbera G; Chiozzi RZ; Digiacomo L; Peruzzi G; Caracciolo G; Laganà A
Colloids Surf B Biointerfaces; 2017 May; 153():263-271. PubMed ID: 28273493
[TBL] [Abstract][Full Text] [Related]
8. Carbohydrate-Based Nanocarriers Exhibiting Specific Cell Targeting with Minimum Influence from the Protein Corona.
Kang B; Okwieka P; Schöttler S; Winzen S; Langhanki J; Mohr K; Opatz T; Mailänder V; Landfester K; Wurm FR
Angew Chem Int Ed Engl; 2015 Jun; 54(25):7436-40. PubMed ID: 25940402
[TBL] [Abstract][Full Text] [Related]
9. Proteomic and Lipidomic Analysis of Nanoparticle Corona upon Contact with Lung Surfactant Reveals Differences in Protein, but Not Lipid Composition.
Raesch SS; Tenzer S; Storck W; Rurainski A; Selzer D; Ruge CA; Perez-Gil J; Schaefer UF; Lehr CM
ACS Nano; 2015 Dec; 9(12):11872-85. PubMed ID: 26575243
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
[TBL] [Abstract][Full Text] [Related]
11. Nanoparticle-Protein Interaction: The Significance and Role of Protein Corona.
Ahsan SM; Rao CM; Ahmad MF
Adv Exp Med Biol; 2018; 1048():175-198. PubMed ID: 29453539
[TBL] [Abstract][Full Text] [Related]
12. Tailored Dual PEGylation of Inorganic Porous Nanocarriers for Extremely Long Blood Circulation in Vivo.
Nissinen T; Näkki S; Laakso H; Kučiauskas D; Kaupinis A; Kettunen MI; Liimatainen T; Hyvönen M; Valius M; Gröhn O; Lehto VP
ACS Appl Mater Interfaces; 2016 Dec; 8(48):32723-32731. PubMed ID: 27934159
[TBL] [Abstract][Full Text] [Related]
13. Nano-Bio Interactions in Cancer: From Therapeutics Delivery to Early Detection.
Liu Y; Wang J; Xiong Q; Hornburg D; Tao W; Farokhzad OC
Acc Chem Res; 2021 Jan; 54(2):291-301. PubMed ID: 33180454
[TBL] [Abstract][Full Text] [Related]
14. A novel scavenging tool for cancer biomarker discovery based on the blood-circulating nanoparticle protein corona.
Hadjidemetriou M; Al-Ahmady Z; Buggio M; Swift J; Kostarelos K
Biomaterials; 2019 Jan; 188():118-129. PubMed ID: 30343255
[TBL] [Abstract][Full Text] [Related]
15. Anti-polyethylene glycol antibodies alter the protein corona deposited on nanoparticles and the physiological pathways regulating their fate in vivo.
Grenier P; Viana IMO; Lima EM; Bertrand N
J Control Release; 2018 Oct; 287():121-131. PubMed ID: 30138715
[TBL] [Abstract][Full Text] [Related]
16. Effect of polyethyleneglycol (PEG) chain length on the bio-nano-interactions between PEGylated lipid nanoparticles and biological fluids: from nanostructure to uptake in cancer cells.
Pozzi D; Colapicchioni V; Caracciolo G; Piovesana S; Capriotti AL; Palchetti S; De Grossi S; Riccioli A; Amenitsch H; Laganà A
Nanoscale; 2014 Mar; 6(5):2782-92. PubMed ID: 24463404
[TBL] [Abstract][Full Text] [Related]
17. Surface Functionalization of Nanoparticles with Polyethylene Glycol: Effects on Protein Adsorption and Cellular Uptake.
Pelaz B; del Pino P; Maffre P; Hartmann R; Gallego M; Rivera-Fernández S; de la Fuente JM; Nienhaus GU; Parak WJ
ACS Nano; 2015 Jul; 9(7):6996-7008. PubMed ID: 26079146
[TBL] [Abstract][Full Text] [Related]
18. The interaction between nanoparticles-protein corona complex and cells and its toxic effect on cells.
Liu N; Tang M; Ding J
Chemosphere; 2020 Apr; 245():125624. PubMed ID: 31864050
[TBL] [Abstract][Full Text] [Related]
19. Regulation of in vivo behavior of TAT-modified liposome by associated protein corona and avidity to tumor cells.
Amin M; Bagheri M; Mansourian M; Jaafari MR; Ten Hagen TL
Int J Nanomedicine; 2018; 13():7441-7455. PubMed ID: 30532532
[TBL] [Abstract][Full Text] [Related]
20. How Corona Formation Impacts Nanomaterials as Drug Carriers.
Gupta MN; Roy I
Mol Pharm; 2020 Mar; 17(3):725-737. PubMed ID: 31939673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
